The abstract is read at the publisher; the summary is JClub's.
OPB-111077, a Complex I inhibitor, suppresses OXPHOS and shows anti-tumour activity, with synergism versus bendamustine in mouse tumour models.
- Why it matters: Resistance to anti-tumour drugs can involve metabolic shifts toward oxidative phosphorylation, so targeting OXPHOS alongside DNA-damaging therapy may improve treatment.
- What they did: The authors measured oxygen consumption, ATP production, and Complex I activity, then tested OPB-111077 alone and with bendamustine in cell lines and xenograft models, including CRISPR screening and metabolomics.
- The result: OPB-111077 synergized with bendamustine, with combined inhibition of OXPHOS and glycolysis; bendamustine reprogrammed cells into an OXPHOS-dominant state, and the approach is in a Phase 1 trial (NCT04049825) for relapsed/refractory diffuse large B-cell lymphoma.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.